Non-surgical management of central giant cell granuloma with calcitonin nasal spray in an 8-year-old patient: Radiographic presentation

---

Case Report

Author Details : Amina Sultan*, Ravi S Batra

Volume : 6, Issue : 4, Year : 2020

Article Page : 312-315

https://doi.org/10.18231/j.ijohd.2020.064

Suggest article by email

Get Permission

---

Abstract

The central giant cell granuloma (CGCG) presents as a benign, painless, slow-growing swelling of the jaw. These lesions are reported more frequently in females and most often occur in the mandible. Radiographically, it presents as a distinct delineated bony pathology with a loss of lamina dura around teeth. There can be frequent signs of displacement of teeth and tooth germs. Currently, the usually followed surgical treatment of the CGCG ranges from simple curettage to en -bloc resection. The extensive resection of aggressive and larger lesions inevitably results in the loss of teeth and tooth germs, especially in younger patients. Since, calcitonin has a direct inhibiting effect on osteoclasts and is efficient in controlling diseases with increased osteoclast activity, such as Paget’s disease, and osteoclastic bone metastases, hence serve as a promising alternative. This paper presents the effectiveness and safety of Calcitonin nasal spray, in the management of a CGCG of the jaw, in an 8-year-old patient who was given calcitonin as first-line therapy.

Keywords: Bony pathology, Calcitonin nasal spray, Central giant cell granuloma (CGCG), Enbloc resection, Management, Swellings of jaws.

How to cite : Sultan A , Batra R S , Non-surgical management of central giant cell granuloma with calcitonin nasal spray in an 8-year-old patient: Radiographic presentation. Int J Oral Health Dent 2020;6(4):312-315

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.